Overexpression of Nucleolin and Associated Genes in Prostate Cancer

Prostate cancer (PCa) is the second most frequent cancer and the fifth leading cause of cancer death in men worldwide. If local PCa presents a favorable prognosis, available treatments for advanced PCa display limiting benefits due to therapeutic resistances. Nucleolin (NCL) is a ubiquitous protein involved in numerous cell processes, such as ribosome biogenesis, cell cycles, or angiogenesis. NCL is overexpressed in several tumor types in which it has been proposed as a diagnostic and prognostic biomarker. In PCa, NCL has mainly been studied as a target for new therapeutic agents. Nevertheless, little data are available concerning its expression in patient tissues. Here, we investigated the expression of NCL using a new cohort from Mondor Hospital and data from published cohorts. Results were then compared with NCL expression using in vitro models. NCL was overexpressed in PCa tissues compared to the normal tissues, but no prognostic values were demonstrated. Nine genes were highly co-expressed with NCL in patient tissues and tumor prostate cell lines. Our data demonstrate that NCL is an interesting diagnostic biomarker and propose a signature of genes co-expressed with NCL.

[1]  A. De la taille,et al.  Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance , 2021, Cancers.

[2]  K. Rahbar,et al.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.

[3]  J. Zabell.  Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer , 2021, 50 Studies Every Urologist Should Know.

[4]  Xuan Wei,et al.  Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma , 2021, Cancer management and research.

[5]  T. Tammela,et al.  Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. , 2020, The New England journal of medicine.

[6]  Joseph J. Mills,et al.  NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs , 2020, Cancers.

[7]  Brian Craft,et al.  Visualizing and interpreting cancer genomics data via the Xena platform , 2020, Nature Biotechnology.

[8]  M. Lewandowska,et al.  Nucleolin and Nucleophosmin Expression in Gleason 3 and Gleason 4 Prostate Cancer With Seminal Vesicles Invasion (pT3b) , 2020, AntiCancer Research.

[9]  D. Gautheret,et al.  Reference-free transcriptome exploration reveals novel RNAs for prostate cancer diagnosis , 2019, Life Science Alliance.

[10]  S. M. Taghdisi,et al.  Therapeutic applications of AS1411 aptamer, an update review. , 2019, International journal of biological macromolecules.

[11]  Ga Young Lee,et al.  Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway , 2018, Nature Communications.

[12]  F. Saad,et al.  Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.

[13]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[14]  S. M. Taghdisi,et al.  A Novel AS1411 Aptamer-Based Three-Way Junction Pocket DNA Nanostructure Loaded with Doxorubicin for Targeting Cancer Cells in Vitro and in Vivo. , 2018, Molecular pharmaceutics.

[15]  Xuenong Zhang,et al.  Nucleolin-Targeting AS1411-Aptamer-Modified Graft Polymeric Micelle with Dual pH/Redox Sensitivity Designed To Enhance Tumor Therapy through the Codelivery of Doxorubicin/TLR4 siRNA and Suppression of Invasion. , 2018, Molecular pharmaceutics.

[16]  P. Bouvet,et al.  Multifaceted Nucleolin Protein and Its Molecular Partners in Oncogenesis. , 2018, Advances in protein chemistry and structural biology.

[17]  G. Andriole,et al.  Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. , 2017, European urology focus.

[18]  P. de la Grange,et al.  Alternative splicing of CNOT7 diversifies CCR4–NOT functions , 2017, Nucleic acids research.

[19]  K. Pienta,et al.  Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells , 2017, Clinical genitourinary cancer.

[20]  S. Varambally,et al.  Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer , 2017, The Prostate.

[21]  A. Bardelli,et al.  Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. , 2016, Cancer research.

[22]  M. Rubin,et al.  The Molecular Evolution of Castration-resistant Prostate Cancer. , 2016, European urology focus.

[23]  Y. Wen,et al.  Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1 , 2016, Tumor Biology.

[24]  G. Massonnet,et al.  Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization , 2016, PloS one.

[25]  Ming Qin,et al.  Prostate cancer characterization by optical contrast enhanced photoacoustics , 2016, SPIE BiOS.

[26]  S. Terry,et al.  Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer , 2016, Oncotarget.

[27]  Francesca Salipur,et al.  Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation , 2015, Molecular oncology.

[28]  P. Bouvet,et al.  The roles of nucleolin subcellular localization in cancer. , 2015, Biochimie.

[29]  Zhaohai Wang,et al.  Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy , 2014, Diagnostic Pathology.

[30]  Peng Zhang,et al.  Phosphorylation and changes in the distribution of nucleolin promote tumor metastasis via the PI3K/Akt pathway in colorectal carcinoma , 2014, FEBS letters.

[31]  J. Silberring,et al.  A comparative study of glycoproteomes in androgen-sensitive and -independent prostate cancer cell lines , 2013, Molecular and Cellular Biochemistry.

[32]  W. Qiu,et al.  Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer , 2013, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[33]  Y. Kloog,et al.  Disrupting the Oncogenic Synergism between Nucleolin and Ras Results in Cell Growth Inhibition and Cell Death , 2013, PloS one.

[34]  A. Sabichi,et al.  Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. , 2013, Blood.

[35]  Michael A. Freitas,et al.  In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation , 2013, The Journal of experimental medicine.

[36]  C. Parker,et al.  A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. , 2013, European urology.

[37]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[38]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[39]  A. Giordano,et al.  Glycosilated nucleolin as marker for human gliomas , 2012, Journal of cellular biochemistry.

[40]  Hua Zhou,et al.  EBP1 inhibits translation of androgen receptor mRNA in castration resistant prostate cancer cells. , 2011, Anticancer research.

[41]  D. Martel-Renoir,et al.  The synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells , 2011, BMC Cancer.

[42]  A. van Dorsselaer,et al.  A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins. , 2011, Cancer research.

[43]  P. Bates,et al.  Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. , 2011, Cancer research.

[44]  P. Bates,et al.  A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. , 2010, Cancer research.

[45]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[46]  C. Castilla,et al.  Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer. , 2010, Urology.

[47]  Douglas B. Evans,et al.  High Levels of Nucleolar Expression of Nucleolin Are Associated with Better Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma , 2010, Clinical Cancer Research.

[48]  Kazutoshi Fujita,et al.  Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. , 2009, Human pathology.

[49]  John O Trent,et al.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. , 2009, Experimental and molecular pathology.

[50]  Sven Christian,et al.  Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature , 2009, Angiogenesis.

[51]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[52]  J. Lowe,et al.  Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. , 2008, Neuro-oncology.

[53]  P. Albanese,et al.  Suppression of Tumor Growth and Angiogenesis by a Specific Antagonist of the Cell-Surface Expressed Nucleolin , 2008, PloS one.

[54]  R. Pinkas-Kramarski,et al.  Identification of Nucleolin as New ErbB Receptors- Interacting Protein , 2008, PloS one.

[55]  L. Chung,et al.  Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells , 2006, BMC Cancer.

[56]  Hubing Shi,et al.  The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. , 2006, Blood.

[57]  Mark W. Ball,et al.  AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. , 2006, Molecular cancer therapeutics.

[58]  J. Courty,et al.  Pleiotrophin inhibits HIV infection by binding the cell surface‐expressed nucleolin , 2005, The FEBS journal.

[59]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[60]  Erkki Ruoslahti,et al.  Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels , 2003, The Journal of cell biology.

[61]  M. Dietel,et al.  Nucleolin as Activator of Human Papillomavirus Type 18 Oncogene Transcription in Cervical Cancer , 2002, The Journal of experimental medicine.

[62]  M. Hirai,et al.  Nuclear Targeting by the Growth Factor Midkine , 2002, Molecular and Cellular Biology.

[63]  S. Goueli,et al.  Androgenic regulation of phosphorylation and stability of nucleolar protein nucleolin in rat ventral prostate , 1994, The Prostate.

[64]  C. Lehner,et al.  Major nucleolar proteins shuttle between nucleus and cytoplasm , 1989, Cell.